Loxo Oncology, Inc.

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Official Title: 
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Brief Summary: 
Expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.
Detailed Description: 

N/A for expanded access

Available
EA Type
Individual Patients
Treatment IND/Protocol
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration

Drug: LOXO-292
Open-label expanded access

Eligibility Criteria: 

Inclusion Criteria:

- Diagnosis of cancer with RET activation, who are not eligible for an ongoing LOXO-292 clinical trial and are medically suitable for treatment with LOXO-292

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor

Eligibility Gender: 
All
Countries: 
Australia, Spain, United States
Locations: 

Mayo Clinic Hospital
Scottsdale, Arizona, 85054

Investigator: Nina Karlin

Investigator: Nina Karlin, MD

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158

Investigator: Alain Algazi, MD

Investigator: Alain Algazi, MD

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Torrance, California, 90502

Investigator: Mykola Onyshchenko, MD

Investigator: Mykola Onshchenko, MD

Memorial Regional Hospital
Hollywood, Florida, 33021

Investigator: Luis Raez, MD

Investigator: Luis Raez, MD

Mayo Clinic Hospital
Jacksonville, Florida, 32224

Investigator: Victor Bernet, MD

Investigator: Victor Bernet, MD

AdventHealth Orlando
Orlando, Florida, 32804

Investigator: Mark Socinski, MD

Investigator: Mark Socinski, MD

Tallahassee Memorial Hospital
Tallahassee, Florida, 32308

Investigator: Karen Russell, MD

Investigator: Karen Russell, MD

University Cancer and Blood Center
Athens, Georgia, 30607

Investigator: Petros Nikolinakos, MD

Investigator: Petros Nikolinakos, MD

Emory University
Atlanta, Georgia, 30322

Investigator: Taofeek Owonikoko, MD

Investigator: Taofeek Owonikoko, MD

Massachusetts General Hospital
Boston, Massachusetts, 02114

Investigator: Lori Wirth, MD

Investigator: Lori Wirth, MD

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215

Investigator: Geoffrey Oxnard, MD

Investigator: Geoffrey Oxnard, MD

University of Michigan
Ann Arbor, Michigan, 48109

Investigator: Francis Worden, MD

Investigator: Francis Worden, MD

START Midwest
Grand Rapids, Michigan, 49546

Investigator: Nehal Lakhani, MD

Investigator: Nehal Lakhani, MD

Mayo Clinic Hospital
Rochester, Minnesota, 55905

Investigator: John Morris, MD

Investigator: John Morris, MD

Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169

Investigator: Fadi Braiteh, MD

Investigator: Fadi Braiteh, MD

Memorial Sloan Kettering Cancer Center
New York, New York, 10065

Investigator: Alexander Drilon, MD

Investigator: Alexander Drilon, MD

Cleveland Clinic
Cleveland, Ohio, 44195

Investigator: Nathan Pennell, MD

Investigator: Nathan Pennell, MD

M.D. Anderson Cancer Center
Houston, Texas, 77030

Investigator: Vivek Subbiah, MD

Investigator: Vivek Subbiah, MD

Oncology Consultants
Houston, Texas, 77030

Investigator: Julio Peguero, MD

Investigator: Julio Peguero, MD

Virginia Cancer Specialists
Fairfax, Virginia, 22031

Investigator: Alexander Spira, MD

Investigator: Alexander Spira, MD

Contacts: 

Patient Advocacy
888-406-9574
LoxoNPP@UBC.com

Patient Advocacy
855-RET-4-292 (855-738-4292)
clinicaltrials@loxooncology.com

Jen Kherani, MD
Study Director
Loxo Oncology

Loxo Oncology, Inc.
Eli Lilly and Company
EA Number: 
MeSH Terms: 
Thyroid Neoplasms, Thyroid Cancer, Papillary, Thyroid Diseases
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.